Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease). The peptide is also under evaluation for potential prophylactic therapeutic benefits as well.
HT-002 is at the preclinical stage of development.
In June 2020, Hoth entered a research agreement with Virginia Commonwealth University (“VCU”) to develop and optimize the novel peptide therapeutic. Preclinical results are expected in Q1 2021.
May 20, 2020 Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic
 |